BridgeBio Oncology Therapeutics reported a net loss of $34.2 million for the third quarter of 2026, an improvement from the $44.8 million loss in the prior year period. Total assets decreased to $346.2 million from $448.4 million at year-end 2025, primarily driven by a significant reduction in cash and cash equivalents as the company continues to fund its research and development operations.
BridgeBio Oncology Therapeutics reported financial results for the third quarter of 2026, highlighting a cash runway expected to fund operations into 2029. The company reported clinical progress for its RAS-pathway inhibitors, including a 75% objective response rate for BBO-8520 in combination with pembrolizumab in certain lung cancer patients. Management expects monotherapy data updates for BBO-11818 and BBO-10203 in the fourth quarter of 2026.
Term
Q3 2026
“The third quarter was an important period for BBOT as we reported updated clinical data for BBO-8520 and delineated our strategic focus. Driven by encouraging clinical data across all three programs we are executing on multiple combinations with the potential for significant patient benefit.”
Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT
“With a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.”
Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT
Yong Ben, M.D., M.B.A. has resigned as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc., effective January 8, 2027. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.